Clinical drug development using dynamic biomarkers to enable personalized health care in Chronic Obstructive Pulmonary Disease

Asger R Bihlet; Morten A Karsdal; Anne-Christine Bay-Jensen; Simon Read; Jacob Hull Kristensen; Jannie Marie Bülow Sand; Diana Julie Leeming; Jeppe Ragnar Andersen; Peter Lange; Jørgen Vestbo

doi:10.1378/chest.15-0296

Clinical drug development using dynamic biomarkers to enable personalized health care in Chronic Obstructive Pulmonary Disease

Asger R Bihlet, Morten A Karsdal, Anne-Christine Bay-Jensen, Simon Read, Jacob Hull Kristensen, Jannie Marie Bülow Sand, Diana Julie Leeming, Jeppe Ragnar Andersen, Peter Lange, Jørgen Vestbo

18 Citations (Scopus)

Abstract

Despite massive investments in development of novel treatments for heterogeneous diseases such as Chronic Obstructive Pulmonary Disease (COPD), the resources spent have only benefitted a fraction of the population treated. Personalized Health Care to guide selection of a suitable patient population already in the clinical development of new compounds could offer a solution. In this review, we discuss past successes and failures in drug development and biomarker research in COPD. We describe research in COPD phenotypes, and the required characteristics of a suitable biomarker for identifying patients at higher risk of progression. We review the role of extra-cellular matrix proteins found to be upregulated in COPD. Novel biomarkers of connective tissue remodeling which may provide added value for a personalized approach by detecting subgroups of patients with active disease suitable for pharmacological intervention are discussed.

Original language	English
Journal	Chest
Volume	148
Issue number	1
Pages (from-to)	16-23
Number of pages	8
ISSN	0012-3692
DOIs	https://doi.org/10.1378/chest.15-0296
Publication status	Published - Jul 2015

Access to Document

10.1378/chest.15-0296

Cite this

@article{50b2e62886b049e8a624814af0660733,

title = "Clinical drug development using dynamic biomarkers to enable personalized health care in Chronic Obstructive Pulmonary Disease",

abstract = "Despite massive investments in development of novel treatments for heterogeneous diseases such as Chronic Obstructive Pulmonary Disease (COPD), the resources spent have only benefitted a fraction of the population treated. Personalized Health Care to guide selection of a suitable patient population already in the clinical development of new compounds could offer a solution. In this review, we discuss past successes and failures in drug development and biomarker research in COPD. We describe research in COPD phenotypes, and the required characteristics of a suitable biomarker for identifying patients at higher risk of progression. We review the role of extra-cellular matrix proteins found to be upregulated in COPD. Novel biomarkers of connective tissue remodeling which may provide added value for a personalized approach by detecting subgroups of patients with active disease suitable for pharmacological intervention are discussed.",

author = "Bihlet, {Asger R} and Karsdal, {Morten A} and Anne-Christine Bay-Jensen and Simon Read and Kristensen, {Jacob Hull} and Sand, {Jannie Marie B{\"u}low} and Leeming, {Diana Julie} and Andersen, {Jeppe Ragnar} and Peter Lange and J{\o}rgen Vestbo",

year = "2015",

month = jul,

doi = "10.1378/chest.15-0296",

language = "English",

volume = "148",

pages = "16--23",

journal = "Chest",

issn = "0012-3692",

publisher = "American College of Chest Physicians",

number = "1",

}

TY - JOUR

T1 - Clinical drug development using dynamic biomarkers to enable personalized health care in Chronic Obstructive Pulmonary Disease

AU - Bihlet, Asger R

AU - Karsdal, Morten A

AU - Bay-Jensen, Anne-Christine

AU - Read, Simon

AU - Kristensen, Jacob Hull

AU - Sand, Jannie Marie Bülow

AU - Leeming, Diana Julie

AU - Andersen, Jeppe Ragnar

AU - Lange, Peter

AU - Vestbo, Jørgen

PY - 2015/7

Y1 - 2015/7

N2 - Despite massive investments in development of novel treatments for heterogeneous diseases such as Chronic Obstructive Pulmonary Disease (COPD), the resources spent have only benefitted a fraction of the population treated. Personalized Health Care to guide selection of a suitable patient population already in the clinical development of new compounds could offer a solution. In this review, we discuss past successes and failures in drug development and biomarker research in COPD. We describe research in COPD phenotypes, and the required characteristics of a suitable biomarker for identifying patients at higher risk of progression. We review the role of extra-cellular matrix proteins found to be upregulated in COPD. Novel biomarkers of connective tissue remodeling which may provide added value for a personalized approach by detecting subgroups of patients with active disease suitable for pharmacological intervention are discussed.

AB - Despite massive investments in development of novel treatments for heterogeneous diseases such as Chronic Obstructive Pulmonary Disease (COPD), the resources spent have only benefitted a fraction of the population treated. Personalized Health Care to guide selection of a suitable patient population already in the clinical development of new compounds could offer a solution. In this review, we discuss past successes and failures in drug development and biomarker research in COPD. We describe research in COPD phenotypes, and the required characteristics of a suitable biomarker for identifying patients at higher risk of progression. We review the role of extra-cellular matrix proteins found to be upregulated in COPD. Novel biomarkers of connective tissue remodeling which may provide added value for a personalized approach by detecting subgroups of patients with active disease suitable for pharmacological intervention are discussed.

U2 - 10.1378/chest.15-0296

DO - 10.1378/chest.15-0296

M3 - Review

C2 - 25856563

SN - 0012-3692

VL - 148

SP - 16

EP - 23

JO - Chest

JF - Chest

IS - 1

ER -

Clinical drug development using dynamic biomarkers to enable personalized health care in Chronic Obstructive Pulmonary Disease

Abstract

Access to Document

Fingerprint

Cite this